Skip to main content
. 2019 May 29;116(24):11972–11977. doi: 10.1073/pnas.1901987116

Fig. 4.

Fig. 4.

Effects of PFTBA@Alb on mice platelet function in the presence of tumor cells or tumor cell secretions. (A) Representative photos of clot retraction test induced by the hybrid platelet activator (CT26 tumor cell secretions, thrombin, and collagen). (B and C) Quantification of the clot weight and serum weight of clot retraction test at 90 min after mixing with different concentrations of PFTBA@Alb or ticagrelor (40 μg/mL) or vehicle (albumin, 1.3 mg/mL; n = 3). (D and E) Representative fluorescent images of platelet aggregation induced by CT26 or 4T1 tumor cell or CT26 tumor cell secretions after treating with PFTBA@Alb. Platelets were prelabeled with CFSE. (F) Quantification of the size of platelet aggregation induced by tumor cell secretions after treating with different concentrations of PFTBA@Alb (n = 3). (G–I) Platelet granule secretions (ATP, 5-HT, and angiopoietin-1) induced by tumor cell secretions after treating with ticagrelor or different concentrations of PFTBA@Alb.